Dr Reddy’s Tells Delhi High Court It Will Not Launch Diabetes Drug after Novo Nordisk Objects
Bar  and  Bench 26 March 2026
Dr. Reddy’s Laboratories on Tuesday told the Delhi High Court that it will not commercially manufacture or sell oral tablet Semaglutide falling within the patented range claimed by Novo Nordisk (Novo Nordisk Vs Dr Reddy's).
 
The assurance was given before Justice Tushar Rao Gedela during the hearing a suit filed by Novo Nordisk alleging patent infringement of its oral semaglutide formulations. The drug is used to manage type 2 diabetes.
 
"The defendant has agreed not to commercially manufacture, sale, supply/export, offer for sale Semaglutide (Oral Tablet), comprising Semaglutide and salt(s) of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC), wherein the amount of said salt(s) of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is in the range of 0.6 - 2.1 mmol; wherein the amount of the GLP-1 agonist Semaglutide is in the range of 0.01 mg to 100 mg as claimed under Claim 1 of the plaintiffs’ patent no.IN 325669," the Bench recorded in the order.
 
Novo Nordisk moved the Court claiming that Dr Reddy’s proposed oral semaglutide products infringe its patent covering a specific formulation of the drug.
 
During the hearing of its plea on Wednesday, counsel for Dr Reddy’s submitted that the company would not commercially manufacture or sell oral semaglutide products that fall within the scope of Novo Nordisk’s patent. 
 
As part of the arrangement, Dr Reddy’s agreed to provide advance samples of its proposed products under the brand names “OBEDA” and “MASHLO”, to Novo Nordisk before any commercial launch.
 
Novo Nordisk, in turn, assured that any technical data generated from testing these samples will be kept confidential.
 
"The plaintiffs undertake that the Technical Data/Report arrived at and submitted after the aforesaid samples are tested, shall be kept confidential and not be revealed to any person and would be strictly used for the purpose of this Suit," the Court recorded in the order.
 
The Court also issued summons in the suit to Dr Reddy’s. The company was been directed to file its written statement within 30 days.
 
The case will now be heard on April 24.
 
Courtesy: Bar & Bench
Comments
Corporate CSR Spending Spikes 30% in FY23-24, but Uneven Distribution Raises Policy Concerns: CRISIL
Moneylife Digital Team 26 March 2026
Corporate social responsibility (CSR) spending by listed companies in India has crossed ₹1.22 lakh crore over the past decade, but a significant share of this funding has bypassed the country’s most underdeveloped regions, according...
Anil Ambani Seeks Sandesara-style Debt Settlement, Writes to FM Sitharaman amid ₹40,000 Crore Probe: Reports
Moneylife Digital Team 25 March 2026
Industrialist Anil Ambani has written to Union finance minister (FM) Nirmala Sitharaman seeking a time-bound, structured settlement of outstanding bank dues, invoking the precedent of the Sandesara family case, even as he faces...
NCLAT Refuses Interim Plea by Vedanta To Halt Adani's Resolution Plan for Jaiprakash Associates
SN Thyagarajan (Bar  and  Bench) 25 March 2026
The National Company Law Appellate Tribunal (NCLAT) on Tuesday refused to halt a resolution plan for Jaiprakash Associates Limited (JAL) approved in favour of Adani Enterprises.   A Bench of Chairperson Justice Ashok Bhushan and...
Supreme Court Declines To Intervene in Harpic–Godrej Spic Bottle Dispute, Matter To Proceed to Trial
SN Thyagarajan (Bar  and  Bench) 24 March 2026
The Supreme Court on Monday declined to interfere in an ongoing dispute between Reckitt Benckiser India and Godrej Consumer Products over the shape of bottles used to sell their respective toilet cleaning products, namely Reckitt's...
Free Helpline
Legal Credit
Feedback